Affiliation: Massachusetts General Hospital
- Infrastructure resources for clinical research in amyotrophic lateral sclerosisAlexander V Sherman
Neurological Clinical Research Institute NCRI, Massachusetts General Hospital, Boston, Massachusetts 02129, USA
Amyotroph Lateral Scler Frontotemporal Degener 14:53-61. 2013....
- Proposed BioRepository platform solution for the ALS research communityAlex Sherman
Neurology Clinical Trials Unit, Massachusetts General Hospital, Charlestown, Massachusetts 02129, USA
Amyotroph Lateral Scler 12:11-6. 2011..Utilizing this platform, we have created one of the largest virtual collections of ALS-related specimens available to investigators studying ALS...
- Phase 2 study of sodium phenylbutyrate in ALSMerit E Cudkowicz
Massachusetts General Hospital, Neurology Clinical Trials Unit, 13th Street, Charlestown, MA 02129, USA
Amyotroph Lateral Scler 10:99-106. 2009..While the majority of subjects tolerated higher dosages of NaPB, the lowest dose (9 g/day), was therapeutically efficient in improving histone acetylation levels...
- Arimoclomol at dosages up to 300 mg/day is well tolerated and safe in amyotrophic lateral sclerosisMerit E Cudkowicz
Neurology Clinical Trials Unit, Massachusetts General Hospital, 13th Street, Charlestown, MA 02129, USA
Muscle Nerve 38:837-44. 2008..Arimoclomol CSF levels increased with dose. Arimoclomol was shown to be safe, and it crosses the blood-brain barrier. Serum pharmacokinetic profiles support dosing of three times per day. An efficacy study in ALS is planned...